Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta‐analysis

Published:2013-10-22 Issue:6 Volume:2 Page:862-871
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Yamanaka Kenya¹²,Petrulionis Marius¹,Lin Shibo¹,Gao Chao¹,Galli Uwe¹,Richter Susanne¹,Winkler Susanne³,Houben Philipp¹,Schultze Daniel¹,Hatano Etsuro²,Schemmer Peter¹

Affiliation:

1. Department of General and Transplant Surgery University Hospital of Heidelberg Heidelberg Germany

2. Department of Surgery Graduate School of Medicine Kyoto University Kyoto Japan

3. Novartis Pharma GmbH Nürnberg Germany

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.150

Reference72 articles.

1. Novel advancements in the management of hepatocellular carcinoma in 2008

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

4. mTOR and cancer: many loops in one pathway

5. mTOR Signaling in Growth Control and Disease

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting ageing with rapamycin and its derivatives in humans: a systematic review;The Lancet Healthy Longevity;2024-02

2. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma;Experimental & Molecular Medicine;2024-01-04

3. Everolimus inhibits hepatoblastoma by inducing autophagy‐dependent ferroptosis;Drug Development Research;2023-12-22

4. Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS/MS;Journal of Pharmaceutical and Biomedical Analysis;2023-10

5. The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma;Current Oncology;2023-06-09